Anti-diabetic therapy ameliorates the inflammageing-based cardiometabolic risk profile of people with type 2 diabetes mellitus

Author : Dora Gasparini, Felix M. Wensveen, Tamara Turk Wensveen

Abstract :Aims: Inflammageing, the age-related increase of pro-inflammatory factors in the body, has been shown to be an important risk factor for the development of cardiometabolic disease. Previously, we have shown that diabetes mellitus type 2 aggravates inflammageing associated with the cytotoxic arm of the immune response. However, whether antidiabetic therapy can ameliorate this effect is unknown. Methods: Blood collection for peripheral blood mononuclear cell isolation and anthropometric measurements were performed in patients with uncontrolled (HbA1c ≥7.5) type 2 diabetes (n=32) at time of admission and 6 months after treatment with metformin and SGLT2 inhibitors and/or incretin mimetics. The phenotype, proliferation capacity and cytokine production by cytotoxic lymphocytes were analysed using multiparametric flow cytometry at both time points. Results: Oral anti-diabetic treatment resulted in a reduction of HbA1c levels (from 8.6% ±1.1 to 6.5% ±0.4, p<0.001) Significantly decreased production of tumor necrosis factor-α, Interferon γ and granzyme B from CD8+ T cells and γδ T cells and Granzyme B by natural killer cells were observed in patients with type 2 diabetes mellitus six months after treatment compared to the time of admission. Further analysis indicated that the reduction in the pro-inflammatory profile of immune cells is associated with improved pancreatic β-cell function

Keywords :Inflammageing, Cardiometabolic risk, Cytokines, Diabetes Mellitus, Type 2, Anti-diabetic therapy, Inflammation, Lymphocytes, Cytotoxic, Tumour Necrosis Factor-alpha, Interferon-gamma, Granzyme-B

Conference Name :International Conference on Cardiology and Therapy (ICCT-25)

Conference Place Edinburgh, UK

Conference Date 20th Aug 2025